Barbara Ryan

IVAX LLC discovers, develops, manufactures, and markets generic pharmaceuticals, respiratory drugs, and cancer treatments. It offers drugs for the treatment of multiple sclerosis, brain cancer, asthma, and epilepsy. The company was founded by Phillip Frost and Jane H. Hsiao in 1987 and is headquartered in Weston, FL.

Hartford Investment Management Co. (HIMCO) is a SEC-registered investment advisor headquartered in Hartford, Connecticut. The firm was founded in 1996 by acquiring the business, personnel and corporate name of an affiliate which had been in operation since 1981 and which performed substantially similar services They are a wholly-owned subsidiary of The Hartford Financial Services Group, Inc. (NYSE: HIG). HIMCO provides investment advisory services primarily to institutional clients and registered and unregistered investment companies. The firm also serves as an investment adviser for its affiliates and provides investment advisory services for vehicles that support the product mix of its affiliates.

Adage Capital Management LP (Adage) is a SEC-registered investment advisor and hedge fund manager headquartered in Boston, Massachusetts. The firm was founded by Phil Gross and Robert Atchinson in 2001 and is owned by Adage Capital Partners GP LLC. Adage provides investment advisory services to its sole client, Adage Capital Partners LP (ACP), a private investment fund. The firm does not manage any separate accounts.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Advent Venture Partners LLP (AVP) is a private equity/venture capital firm founded in 1981 by David James Scott Cooksey. The firm is headquartered in London, United Kingdom.

CalciMedica, Inc. is a holding company, which engages in drug development. It discovers and develops novel small molecule drugs for the treatment of inflammatory and autoimmune disorders and organ transplant rejection. The company was founded by Gonul Velicelebi, Kenneth Stauderman, Anjana Rao, Patrick Hogan, Stefan Feske, Michael Harpold, Tom Reed, and Jack Roos in December 2006 and is headquartered in La Jolla, CA.

Artax Biopharma, Inc. operates as a clinical-stage biopharmaceutical company. It engages in the development of new therapies for autoimmune and inflammatory diseases. The firm develops drugs targeting the interaction between T-cell Receptors (TCR) and Nck, a cytoplasmic adapter protein which plays a role in T-cell activation. The company was founded by Dami? Carulla Tormo in 2013 and is headquartered in Cambridge, MA.

Windgap Medical, Inc. engages in the development of epinephrine autoinjector for the treatment of anaphylaxis. The company was founded was founded by Christopher J. Stepanian and Brent Buchine and is headquartered in Somerville, MA.

Zikani Therapeutics, Inc. is a preclinical-stage company developing and commercializing novel therapeutics. The company was founded by Lawrence G. Miller and Andrew G. Myers in 2014 and is headquartered in Watertown, MA.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

Cornell University is an educational institution that offers undergraduate and post graduate programs. It was founded in 1865 and is based in Ithaca, NY.

Promedior, Inc. is a clinical-stage immunotherapy company, which engages in the development of targeted therapeutics to treat fibrotic diseases. Its proprietary therapeutic platform is based upon Pentraxin-2, an endogenous human protein that plays an important role in regulating the response to fibrosis. The company was founded by Gomer H. Richard, Lawrence M. Kauvar, and Darrell Pilling in April 2006 and is headquartered in Lexington, MA.

Nemucore Medical Innovations, Inc. is a clinical development company. It specializes in the development and commercialization of molecularly targeted therapeutics for the treatment of multi-drug resistant cancers with an emphasis on women's oncology. The company was founded by Timothy P. Coleman, Yuri Lvov, Vladimir Torchilin and Mansoor Amiji in 2008 and is headquartered in Wellesley, MA.

Part of Advent Venture Partners LLP, Advent Life Sciences LLP is a venture capital firm for visionary innovators. The company is based in London, UK. Advent Life Sciences has achieved its first discovery milestone in collaboration with Bristol Myers Squibb, and is focused on the journey from innovative science to an approved medicine or product. The British company has a history of delivering value and is one of the leading venture capital firms in the industry.

Vigeo Therapeutics, Inc. manufactures cancer drugs. It develops therapies designed to reprogram the tumor immune microenvironment by targeting CD36 and CD47 via Tsp-1 induction. The company was founded by Randolph Watnick and Jing Watnick in 2011 and is headquartered in Cambridge, MA.

Part of Vaxxinity, Inc., United Neuroscience Ltd. is an Irish clinical stage biotech company. The company is based in Dublin, Ireland.

Antolrx, Inc. operates in the healthcare industry focusing on biotechnology business. The company was founded by Mark Carthy and is headquartered in Boston, MA.

Arrakis Therapeutics, Inc. operates as a biopharmaceutical company. It develops rna-targeted small molecule medicines focused on neurologic, cancer, and rare genetic diseases. The company was founded by Russell C. Petter, Alan E. Walts, Jennifer C. Petter and Raj Bhikhu Parekh in 2015 and is headquartered in Waltham, MA.

Palvella Therapeutics, Inc. operates as a rare disease biopharmaceutical company. It develops and commercializes pathogenetically targeted therapies for rare genodermatoses with no approved treatments. Its products include QTORIN, PTX-022, PTX-367, and PTX-014. The company was founded by Wesley H. Kaupinen in 2015 and is headquartered in Wayne, PA.

DermBiont, Inc. operates as an early stage biopharmaceutical company that engages in discovery and development of live bacterial products for the treatment of skin diseases. It develops skin microbiome therapeutics platform to treat and prevent skin diseases. The company was founded by Karl R. Beutner, Robert M. Brucker and Nichola Eliovits in 2017 and is headquartered in Boston, MA.

Clear Creek Bio, Inc. engages in the development of therapies that target nucleotide synthesis pathways. The firm focuses on the differentiation blockade in cancer and suppress replication of RNA-based viruses. It uses pharmacodynamic markers to ensure that each patient gets the right drug at the correct dose. The company was founded by David T. Scadden, David B. Sykes, Burt A. Adelman, and Vikram Sheel Kumar in 2017 and is headquartered in Cambridge, MA.

Apnimed, Inc. operates as a clinical-stage company. It discovers novel pharmaceutical therapies for sleep apnea and related disorders. The company was founded by Lawrence G. Miller and Luigi Taranto Montemurro in 2017 and is headquartered in Cambridge, MA.

SG DAN Holdings LLC operates as an investment holding firm. The company is headquartered in New York, NY.

Apic Bio, Inc. engages in the development of treatment for neurological and liver diseases. It offers THRIVE, a platform that silences a mutant gene product and replaces a normal gene product in a single dual function vector. The company was founded by Robert H. Brown, Jr., John Reilly, and Christian Mueller in 2017 and is headquartered in North Cambridge, MA.

Neoseq Ltd. develops and provides healthcare solutions. The company is headquartered in San Diego, CA.

Privo Technologies, Inc. engages in biotechnology company. The firm focuses on oral cancer, intra-opertaive chemotherapy and HPV caused cancers. The company was founded by Manijeh Goldberg and is headquartered in Peabody, MA.

Part of Prilenia Therapeutics BV, Prilenia Therapeutics Development Ltd. is a clinical stage biotech company based in Herzliya, Israel. Prilenia Therapeutics is developing its lead drug candidate, pridopidine, which is a sigma-1 receptor agonist and is in clinical development for the treatment of ALS and Huntington's disease. Pridopidine is currently part of the Healey ALS platform phase 2/3 clinical study and is in a phase 3 trial (PROOF-HD) with the Huntington Study Group, addressing functional capacity in early-stage HD patients. The pridopidine pipeline includes further indications in the pre-clinical phase. The Israeli company was founded by Michael R. Hayden in 2018 with the purpose of developing treatments for neurodegenerative and neurodevelopmental disorders.

PIC Therapeutics, Inc. operates as a biotechnology company, which focuses on transforming the treatment of cancer though the selective modulation of oncogene translation. The company was founded by Richard Peters and Gerhard Wagner and is headquartered in Boston, MA.

Myeloid Therapeutics, Inc. operates as an immuno-oncology company that engages in the development of cell program to cure cancer. It offers ATAK platform, a cell therapy technology. The company was founded by Ronald Vale, Siddhartha Mukherjee, Daniel Getts, and Thomas Cahill in 2019 and is headquartered in Cambridge, MA.

Matrivax Research & Development Corp. is developing human vaccines for the prevention and treatment of life-threatening bacterial diseases. Its pipeline includes two vaccine candidates implementing proprietary streptococcus pneumoniae and clostridium difficile protective antigens. The company was founded in October 2007 and is headquartered in Boston, MA.

Neuroelectrics, Inc. is a company that is developing a therapeutic platform for the treatment of neurological and psychiatric disorders. The company is based in Cambridge, MA and Barcelona, Spain. The company's platform uses neuromodulation, which combines safe and proven neuromodulation capabilities with remote-controlled delivery and personalized treatment protocols to restore and maintain brain health. Neuroelectrics has an expanding pipeline of computationally driven solutions for neurologic and psychiatric disorders. The company was founded by Ana Maiques Valls and Giulio Ruffini, and Ana Maiques Valls has been the CEO since incorporation.

Arcturus Studios Holdings, Inc. specializes in editing and compressing volumetric video through their holostream and holosuite products. Arcturus Studios Holdings is based in Beverly Hills, CA and has subsidiaries in Canada. These products provide adaptive streaming volumetric video for uninterrupted experiences delivered on demand. The company has received positive feedback from clients such as Crescent Studios, Far East Company, Inc., and NTT Docomo, Inc. for their professional-grade tools and ability to anticipate customer needs. Holoedit and holosuite have been used in various projects, including those featuring BTS and the 2019 Samsung Developer Conference. The company was founded by Devin Horsman, Andy Stack, and Ewan Johnson, and the CEO is Kamal Mistry.